Istradefylline (Nourianz)

Istradefylline (Nourianz)

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Istradefylline (Nourianz)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Istradefylline (Nourianz)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Istradefylline (Nourianz) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Istradefylline (brand name Nourianz; development code KW-6002) is an oral adenosine A2A receptor antagonist developed by Kyowa Kirin for the treatment of "off" episodes in adults with [Parkinson's disease](/diseases/parkinsons-disease) receiving [levodopa](/therapeutics/levodopa)/carbidopa. It is the first non-dopaminergic drug approved by the FDA for [Parkinson's disease](/diseases/parkinsons-disease) in over two decades and represents the first clinical application of adenosine receptor pharmacology in [neurodegeneration](/diseases).[@mller2020] [@kondo2015]

The FDA approved istradefylline on August 27, 2019, as an add-on treatment to [levodopa](/therapeutics/levodopa)/carbidopa in PD patients experiencing "off" episodes — periods when PD medication is not working optimally and motor symptoms return. Istradefylline had been approved in Japan since 2013, where it was the first adenosine A2A antagonist to reach the market for any indication.[@kondo2015] [@schiffmann2007]

Istradefylline (Nourianz)

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Istradefylline (Nourianz)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Istradefylline (Nourianz)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Istradefylline (Nourianz) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Istradefylline (brand name Nourianz; development code KW-6002) is an oral adenosine A2A receptor antagonist developed by Kyowa Kirin for the treatment of "off" episodes in adults with [Parkinson's disease](/diseases/parkinsons-disease) receiving [levodopa](/therapeutics/levodopa)/carbidopa. It is the first non-dopaminergic drug approved by the FDA for [Parkinson's disease](/diseases/parkinsons-disease) in over two decades and represents the first clinical application of adenosine receptor pharmacology in [neurodegeneration](/diseases).[@mller2020] [@kondo2015]

The FDA approved istradefylline on August 27, 2019, as an add-on treatment to [levodopa](/therapeutics/levodopa)/carbidopa in PD patients experiencing "off" episodes — periods when PD medication is not working optimally and motor symptoms return. Istradefylline had been approved in Japan since 2013, where it was the first adenosine A2A antagonist to reach the market for any indication.[@kondo2015] [@schiffmann2007]

Mechanism of Action

Adenosine A2A Receptors in the Basal Ganglia

The mechanism of istradefylline is distinct from all other approved PD therapies because it acts on the adenosinergic system rather than the dopaminergic system. Understanding its mechanism requires knowledge of [basal ganglia](/brain-regions/basal-ganglia) circuit physiology: [@schwarzschild2006]

In the striatum, medium spiny [neurons](/entities/neurons) (MSNs) of the indirect pathway co-express dopamine D2 receptors and adenosine A2A receptors. Under normal conditions, dopamine binding to D2 receptors on these [medium spiny neurons](/cell-types/medium-spiny-neurons) inhibits the indirect pathway, facilitating movement. Adenosine, acting at A2A receptors on the same [neurons](/entities/neurons), has the opposite effect — it excites the indirect pathway and thereby suppresses movement.[@schiffmann2007] [@jenner2021]

In [Parkinson's disease](/diseases/parkinsons-disease), the loss of [dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc) in the [substantia nigra](/brain-regions/substantia-nigra) pars compacta reduces dopaminergic input to the striatum. This causes: [@fuxe2007]

A2A Receptor Antagonism

Istradefylline blocks A2A receptors selectively (Ki = 2.2 nM for A2A vs. >1000 nM for A1 receptors), releasing the indirect pathway from the excitatory influence of adenosine. This: [@nourianz2019]

• Restores the balance between the direct and indirect pathways
• Reduces excessive GABAergic output from the indirect pathway
• Improves motor function without directly increasing dopaminergic activity
• Provides a complementary mechanism to [levodopa](/therapeutics/levodopa) therapy[@jenner2021]

Interaction with Dopaminergic Signaling

At the intracellular level, A2A and D2 receptors form functional heteromers on [medium spiny neurons](/cell-types/medium-spiny-neurons). Adenosine A2A stimulation allosterically reduces D2 receptor affinity for dopamine and opposes D2-mediated intracellular signaling (via opposing effects on adenylyl cyclase and cAMP). By blocking A2A, istradefylline enhances the functional efficacy of dopamine at D2 receptors, synergizing with exogenous dopamine from [levodopa](/therapeutics/levodopa) therapy.[@fuxe2007] [@nourianz]

Pharmacology

Pharmacokinetics

• Absorption: Rapidly absorbed orally; peak plasma concentration in 1–4 hours. High-fat meals increase exposure by approximately 20% but do not alter efficacy
• Distribution: High protein binding (98%); volume of distribution ~44 L
• Metabolism: Primarily metabolized by CYP3A4 and CYP1A1/1A2. Major metabolite M1 is inactive
• Half-life: Terminal elimination half-life of approximately 46–83 hours, supporting once-daily dosing
• Excretion: Primarily eliminated via hepatic metabolism; renal excretion of unchanged drug is <1%[@nourianz2019]

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Increase istradefylline exposure; maximum dose should not exceed 20 mg/day
• CYP3A4 inducers (e.g., rifampin, carbamazepine): Decrease istradefylline exposure; may reduce efficacy
• Tobacco smoking: Induces CYP1A1/1A2 and may decrease istradefylline levels
• No clinically significant interactions with [levodopa](/therapeutics/levodopa)/carbidopa, dopamine agonists, or [MAO-B inhibitors](/therapeutics/mao-b-inhibitors)[@nourianz2019]

Dosing

• Recommended starting dose: 20 mg once daily as adjunctive therapy to [levodopa](/therapeutics/levodopa)/carbidopa
• Maximum dose: 40 mg once daily
• Hepatic impairment: Maximum 20 mg/day in moderate hepatic impairment (Child-Pugh B); not recommended in severe impairment
• Available as film-coated tablets (20 mg and 40 mg)[@nourianz2019]

Clinical Trials

Pivotal Trials

Istradefylline was evaluated in four randomized, double-blind, placebo-controlled Phase III trials enrolling a total of 1,143 participants with [Parkinson's disease](/diseases/parkinsons-disease) experiencing ≥2 hours of "off" time daily while on stable [levodopa](/therapeutics/levodopa)/carbidopa therapy (disease duration average ~9 years).[@mller2020] [@lewitt2020]

Study 6002-US-013 (N=231): [@ascherio2001]

• Istradefylline 40 mg/day vs. placebo
• Primary endpoint: Percentage change from baseline in "off" time
• Result: −10.8% (istradefylline) vs. −4.0% (placebo); p=0.03
• Corresponding to −1.8 hours vs. −0.6 hours reduction in daily "off" time

• Istradefylline 20 mg and 40 mg vs. placebo
• Both doses demonstrated significant reductions in "off" time vs. placebo

• Consistent direction of effect, with the Japanese study showing robust efficacy

Long-term Safety

An open-label 52-week extension study demonstrated sustained "off" time reduction and acceptable tolerability with chronic dosing. No evidence of tachyphylaxis or loss of efficacy was observed over the treatment period.[@barajimenez2003]

Safety Profile

Common Adverse Events

In clinical trials, the most frequently reported adverse events were:

• Dyskinesia (17–18% vs. 8% placebo) — may reflect improved [levodopa](/therapeutics/levodopa) efficacy rather than direct toxicity
• Dizziness (3%)
• Constipation (4%)
• Nausea (3%)
• Hallucinations (1–3%)
• Insomnia (2%)

Important Safety Considerations

• Dyskinesia management: If troublesome dyskinesia occurs, reduction of [levodopa](/therapeutics/levodopa) dose may be warranted
• Impulse control disorders: Reported in postmarketing experience, as with other PD medications
• Psychiatric symptoms: Hallucinations and psychotic behavior, particularly in elderly patients
• Hepatic: Not recommended in severe hepatic impairment
• Pregnancy: Category C; not studied in pregnant women[@nourianz]

Clinical Context

Addressing a Therapeutic Gap

In the current PD treatment paradigm, all approved therapies until istradefylline worked by modulating the dopaminergic system — [levodopa](/therapeutics/levodopa), [dopamine agonists](/therapeutics/dopamine-agonists), [MAO-B inhibitors](/therapeutics/mao-b-inhibitors), and [COMT inhibitors](/therapeutics/comt-inhibitors). As [Parkinson's disease](/diseases/parkinsons-disease) progresses, motor fluctuations (wearing-off, "off" episodes) become increasingly difficult to manage with dopaminergic optimization alone. Istradefylline provides a non-dopaminergic mechanism to reduce "off" time, particularly valuable when:

• Increasing [levodopa](/therapeutics/levodopa) dose causes unacceptable dyskinesia or psychiatric side effects
• [Dopamine agonists](/therapeutics/dopamine-agonists) are not tolerated (especially in elderly patients)
• Patients remain with significant "off" time despite optimized dopaminergic therapy[@lewitt2020]

Positioning in Treatment Algorithm

Istradefylline is currently indicated only as adjunctive therapy — not as monotherapy. It is typically added to [levodopa](/therapeutics/levodopa)/carbidopa regimens in patients with motor fluctuations. Guidelines from the American Academy of Neurology and the Movement Disorder Society include istradefylline as an option for managing motor fluctuations, though long-term comparative studies with other adjunctive therapies are limited.

Future Adenosine A2A Research

The approval of istradefylline has stimulated research into other A2A receptor-based approaches:

• Potential cognitive benefits: Preclinical evidence suggests A2A antagonism may have neuroprotective and pro-cognitive effects beyond motor symptom relief
• Application in other neurodegenerative diseases: A2A antagonism is being investigated for potential benefits in [Alzheimer's disease](/diseases/alzheimers-disease) (where adenosine signaling is dysregulated), [Huntington's disease](/mechanisms/huntington-pathway), and [ALS](/diseases/amyotrophic-lateral-sclerosis)
• Caffeine connection: Epidemiological data showing reduced PD risk with caffeine consumption (a non-selective adenosine receptor antagonist) provided the original rationale for developing selective A2A antagonists[@ascherio2001]

See Also

• [Medium Spiny Neurons (MSNs)](/cell-types/medium-spiny-neurons)
• [COMT Inhibitors](/therapeutics/comt-inhibitors)
• [Dopamine Agonists in Parkinson's Disease](/therapeutics/dopamine-agonists)
• [Levodopa](/therapeutics/levodopa)
• [MAO-B Inhibitors](/therapeutics/mao-b-inhibitors)

External Links

• [ClinicalTrials.gov — Istradefylline studies](https://clinicaltrials.gov/search?intr=istradefylline)
• [Nourianz HCP site](https://www.nourianzhcp.com/)
• [FDA Label — Nourianz](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf)

Background

The study of Istradefylline (Nourianz) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Adenosine-Astrocyte Metabolic Reset](/hypothesis/h-41bc2d38) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ADORA2A

• [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;